ADVANCED SOLID TUMORS

This early-stage study tested a new drug called INCA00186, given alone or combined with other immunotherapies, in people with advanced head/neck cancers or certain gastrointestinal cancers. The main goals were to check the safety of the drug, find the best dose, and see if it sho…

This early-stage trial tested a new drug called SIM0501, both alone and combined with an existing cancer drug (olaparib), in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the safety of the drug, see how the body…

This early-stage study aimed to test the safety and find the right dose of a new drug, PF-07265028, for people with advanced cancers that have spread. The drug was tested alone and in combination with another cancer therapy called sasanlimab. The trial was terminated after enroll…

This early-stage study is testing a new drug called ASP2074 in adults with advanced solid tumors that have spread and who have run out of standard treatment options. The main goals are to find a safe dose for future research and to understand what side effects the drug might caus…

This early-stage study tested a new oral drug called ATX-559 in patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and see how the body processes the drug. Researchers also looked for early signs that th…

This early-stage study tested a new oral drug called Debio 0123 in combination with the chemotherapy carboplatin. It aimed to find a safe and effective dose for adults with advanced solid tumors that had stopped responding to prior platinum-based treatments. The main goals were t…

This was a first-in-human study to test the safety and find the right dose of a new immunotherapy drug called FAZ053. It was given alone and in combination with another drug, PDR001, to 154 adults with advanced solid tumors that had stopped responding to standard treatments. The …

This early-stage study tested a new oral drug called BGB-30813, both alone and combined with the immunotherapy drug tislelizumab, in people with advanced cancers that had spread. The main goals were to find safe doses and check for early signs that the treatments might help shrin…

This early-stage study aimed to test the safety and find the right dose of a new drug called BLU-222 for people with advanced solid tumors that have stopped responding to standard treatments. It involved about 50 patients with cancers like breast, ovarian, and gastric cancer. The…

This early-stage study tested a new drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety, how the body processes it, and what side effects it might cause. The trial was termina…

This early-stage study tested the safety of an experimental drug called INCB081776, both alone and combined with another drug, in people with advanced cancers that had stopped responding to standard treatments. The main goal was to find safe dosage levels and understand how the b…

This early-stage study tested a personalized cell therapy called HV-101 for adults with advanced solid tumors that had returned or spread. Doctors planned to extract immune cells from a patient's own tumor, grow them in a lab, and reinfuse them to fight the cancer. The trial was …